Objective-To compare the efficacy and safety of terbinafine 1% cream and clotrimazole 1% cream in the treatment oftinea pedis. Conclusion-These results indicate that a one week course of terbinafine 1% cream is more effective in the treatment of tinea pedis than a four week course of clotrimazole 1% cream, both in terms of mycological cure and effective treatment.
Introduction
Tinea pedis (athlete's foot) is estimated to occur in 15% of the population with the highest incidence among regular users of communal bathing places. The most common and usually successful treatment for tinea pedis is a topical antifungal cream, which must be applied two to three times a day for up to four weeks; the prolonged treatment period probably reflects the primarily fungistatic action of these preparations.' Although cure rates are good when these treatments are used as recommended, the number of applications required per day and the lengthy treatment period may lead to poor compliance by patients and failure of treatment. Clearly a topical treatment with a much shorter duration of treatment would be an advantage. Terbinafine one week. Patients also returned for assessment at week four (end of treatment) and at week six (two weeks after the end of treatment).
MYCOLOGICAL AND CLINICAL ASSESSMENTS
At each week a skin scraping was taken and sent to a central laboratory in Leeds for mycological investigation. This consisted of direct microscopy in 20% potassium hydroxide and culture on Sabouraud glucose agar (plus chloramphenicol 0 05%, actidione 0 5%, w:v) at 27°C for up to two weeks. Any signs and symptoms of infection-namely, erythema, scaling, vesiculation, pustules, crusting, and pruritus-were rated by the physician on the scale 0 =absent, 1=mild, 2= moderate, 3= severe, to give a clinical score (maximum score of 18). A rating was also made of a target lesion (identified at week 0 and being the largest and most severely affected area) by using the same scale. Any adverse events were recorded and scored on the scale of 1 = mild,2 = moderate, 3 = severe.
Patients were classified as mycologically cured if they had negative results on microscopy and culture. Mycologically cured patients with a total signs and symptoms score of -2 (providing this was made up of two "milds" and not one "moderate") were classified as "effectively treated." All other outcomes were classified as "ineffectively treated." Analysis was carried out on an intention to treat basis. Efficacy and mycology results were assessed as follows. For each treatment group the percentage of patients cured was determined. The difference between groups and corresponding 95% confidence intervals was calculated. As the data was of a non-parametric nature, the MantelHaenszel XI test was used to test for significance between treatment groups.
Results
Two hundred and fifty six patients with tinea pedis were entered into the study. Of these, 41 were classified as delayed exclusions (38 patients with negative baseline mycology and three with non-dermatophyte fungal infections). One patient using clotrimazole for paronychia was excluded from the analysis as were three patients who failed to return after the entry visit.
Therefore 211 patients were evaluable, of whom 107 were randomised to terbinafine (75 male, 32 female; mean (range) age 40 (12-81) years) and 104 to clotrimazole (79 male, 25 female; mean (range) age 36 (12-74) years). Table I shows the infecting organisms, and, as expected, the most common causal agent was Trichophyton rubrum.
The mycological cure rates are shown in Four adverse events in the terbinafine group were probably or certainly related to treatment. These included painful stinging and cracks, increased itching, irritation of eyes, and erythema or swelling of skin; one patient stopped terbinafine treatment because of erythema or swelling of skin. In the clotrimazole group three adverse events were probably or certainly related to treatment. Signs and symptoms experienced included erythema, soreness, and a red rash. One patient with cellulitis of the foot, which was probably unrelated to treatment, stopped using clotrimazole.
Discussion
In this study twice daily applications of terbinafine 1% cream for one week (followed by three weeks of placebo) was significantly superior, both in terms of mycological cure and effective treatment, to twice daily applications for four weeks of clotrimazole when compared six weeks after starting treatment. The cure rates with terbinafine 1% cream were high, with 97% of patients mycologically cured and 90% of patients effectively treated. Two weeks after the end of treatment with clotrimazole, however, the cure rates were still rising and if the follow up period had been longer they may have been higher. It is also worth noting that five weeks after the completion of treatment with terbinafine the mycological cure rates were still rising, confirming the findings of other studies which suggest that short duration treatment with terbinafine is not associated with relapse.9 Nevertheless, one must acknowledge that had the follow up period been longer in this study relapses might have occurred, but then the difficulty would have been in distinguishing these relapses from cases of reinfection.
The superiority of terbinafine over clotrimazole, even with a shorter duration of treatment, is probably because terbinafine has a primarily fungicidal mode of action whereas clotrimazole is primarily fungistatic. One has to recognise, however, the theoretical possi-BMJ VOLUME 307 11 SEPTEMBER 1993 Clinical implications cream (50 g tube) . Possibly terbinafine 1% cream will become the preferred topical treatment of tinea pedis.
